NCT04644770 2026-04-13
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Active not recruiting
Janssen Research & Development, LLC
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
University Hospital Heidelberg
University of Hawaii
National Institutes of Health Clinical Center (CC)